Levalbuterol
لِوآلبوترول
🌬️ Respiratory SystemShort-acting beta2-agonist (SABA)
Market / country: 🇺🇸 USA
Xopenex HFA (US)
🧮 Dose calculator
Asthma and chronic lung disease (reversible airflow obstruction) · Regimen source: FDA Xopenex HFA · 2.1
- • Some patients need only 1 puff every 4 h. Needing more signals worsening asthma. Prime with 4 sprays before first use or after 3 days. FDA Xopenex HFA · 2.1FDA Xopenex HFA · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to levalbuterol or racemic albuterol. FDA Xopenex HFA · 4
Warnings
- • Paradoxical bronchospasm; deteriorating asthma; cardiovascular effects; do not exceed recommended dose; hypokalaemia. FDA Xopenex HFA · 5
Formulations
- 45 mcg per actuation (HFA) — inhaler 🇺🇸 USA FDA Xopenex HFA · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Xopenex HFA · 8.1
“Risk Summary There are no adequate and well-controlled studies of XOPENEX HFA in pregnant women.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Xopenex HFA · 8.2
“Risk Summary There are no available data on the presence of levalbuterol in human milk, the effects on the breastfed child, or the effects on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Xopenex HFA · 8.4
“Pediatric Patients 4 Years of Age and Older The safety and efficacy of XOPENEX HFA have been established in pediatric patients 4 years of age and older in an adequate and well-controlled clinical trial [see Adverse Reactions (6) and Clinical Studies (14) ].”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Xopenex HFA · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA021730
- DailyMed (FDA label)FDA Xopenex HFA
- MedlinePlus (NIH)Levalbuterol Oral Inhalation
- WHO ATC/DDD❌ None
- Darooyab (Iran)Levosalbutamol-Oral-Inhalation
🇮🇷 Not found in Iran list Darooyab · G-1473/Levosalbutamol-Oral-Inhalation
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Xopenex HFA · 3FDA Xopenex HFA · 2.1FDA Xopenex HFA · 2.2FDA Xopenex HFA · 4FDA Xopenex HFA · 5FDA Xopenex HFA · 8.1FDA Xopenex HFA · 8.2FDA Xopenex HFA · 8.4FDA Xopenex HFA · 8.5FDA Xopenex HFA · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1473/Levosalbutamol-Oral-Inhalation
- Clinical review⚠ Unverified